(Q38031941)

27 August 2017

title

Temsirolimus: a safety and efficacy review (English)

1 reference

27 August 2017

Ronald M Bukowski

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

6 August 2012

1 reference

Expert Opinion on Drug Safety

27 August 2017

published in

1 reference

27 August 2017

volume

11

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

861-879

1 reference

Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Targeting von Hippel-Lindau pathway in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Renal-cell carcinoma--molecular pathways and therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Therapeutic targets: MTOR and related pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

TOR signalling and control of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Substrates of human hepatic cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Rapamycin down-regulates LDL-receptor expression independently of SREBP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

An emerging role of mTOR in lipid biosynthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Targeted therapies for renal cell carcinoma: review of adverse event management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Renal cell carcinoma: focus on safety and efficacy of temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Temsirolimus-induced glomerulopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

The role of mTOR in memory CD8 T-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Thrombotic events in patients with cancer receiving antiangiogenesis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Managing adverse events in the use of bevacizumab and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Combining antiangiogenics to overcome resistance: rationale and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Metastatic renal cell cancer treatments: an indirect comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.713344

10.1517/14740338.2012.713344

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference